Glial Cell Induction via NFIX Overexpression and Cytokine Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for directed induced differentiation of pluripotent stem cells into glial cells are inefficient, time-consuming, and fail to rapidly produce brain and spinal cord specialized subtype glial cells, limiting research and therapeutic applications for nervous system diseases.
Innovation Solution
A method involving the construction of positive cloned stem cells that overexpress the NFIX gene, combined with the addition of cytokines and cytokine inhibitors, to rapidly induce glial cells, including astrocytes, oligodendrocytes, and microglia, through a three-stage cultivation process, significantly improving induction efficiency and maturity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional stepwise induction method is used to simulate in vivo development, then the differentiation process follows natural development pathways, but the induction time is excessively long (3-6 months)
Solution Approach 1:
The patent applies preliminary action by pre-constructing stem cell lines that overexpress reprogramming factors (NFIA, NFIB, NFIX, SOX9) before induction. This pre-preparation of cellular machinery enables rapid differentiation without requiring lengthy stepwise induction, thus reducing induction time while maintaining differentiation accuracy.
Solution Approach 2:
The patent changes key parameters of the induction process by introducing specific reprogramming factor overexpression and optimized cytokine combinations (BMP4, FGF2, PDGF, etc.) with precise timing and concentrations. These parameter changes accelerate the differentiation process from months to weeks while preserving the reliability of glial cell generation.
2Ease of manufacture
If traditional induction methods are used, then the process is simpler to implement, but the induction efficiency and maturity of obtained glial cells are low
Solution Approach 1:
The patent optimizes multiple parameters including reprogramming factor expression levels, cytokine concentrations and timing, and culture conditions. These parameter optimizations significantly improve induction efficiency and glial cell maturity while maintaining reasonable operational simplicity through standardized protocols.
Solution Approach 2:
By pre-construcing stem cell lines with overexpressing reprogramming factors, the patent eliminates the need for complex stepwise induction protocols. This preliminary preparation simplifies the actual induction process to a more direct and efficient procedure while achieving higher induction efficiency and cell maturity.
3Reliability
If human pluripotent stem cells are used for directed induced differentiation, then the functional characteristics closely match human disease models, but the source of cells is severely limited
Solution Approach 1:
The patent pre-construcing multiple independent stem cell lines that overexpress reprogramming factors, creating a reservoir of readily available starting materials. This preliminary preparation ensures continuous supply of human pluripotent stem cells for differentiation, overcoming source limitations while maintaining disease model accuracy.
Solution Approach 2:
The patent optimizes culture and induction parameters to maximize cell proliferation and differentiation efficiency from human pluripotent stem cells. These parameter optimizations enable efficient generation of sufficient cell numbers from limited starting materials, thus overcoming source availability constraints.
Data Source
AI summary
The present disclosure provides a method for obtaining glial cells in vitro and use thereof. The method comprises: constructing positive cloned stem cells that overexpress a reprogramming factor, wherein the reprogramming factor comprises an NFIX gene; and inducing the positive cloned stem cells to the glial cells by adding a cytokine and/or a cytokine inhibitor. The method can rapidly induce the pluripotent stem cells to differentiate into the glial cells, and the obtained glial cells can be used for preparing cell treatment drugs and in-vitro or in-vivo drug screening kits.